Precigen Virtual R&D Day
Jan 24, 2023 at 4:30 PM EST
Precigen's virtual R&D day event showcased complete clinical trial safety and efficacy data from the Phase 1 dose escalation and expansion cohorts for the PRGN-2012 AdenoVerseTM immunotherapy in recurrent respiratory papillomatosis.
Supporting Materials
View presentation 2.6 MB